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The generation of high-affinity antibodies requires somatic hypermutation (SHM) and class 
switch recombination (CSR) at the immunoglobulin (Ig) locus. Both processes are triggered 
by activation-induced cytidine deaminase (AID) and require 
 
UNG
 
-encoded uracil-DNA 
glycosylase. AID has been suggested to function as an mRNA editing deaminase or as a 
single-strand DNA deaminase. In the latter model, SHM may result from replicative 
incorporation of dAMP opposite U or from error-prone repair of U, whereas CSR may be 
triggered by strand breaks at abasic sites. Here, we demonstrate that extracts of 
 
UNG
 
-
proficient human B cell lines efficiently remove U from single-stranded DNA. In B cell lines 
from hyper-IgM patients carrying 
 
UNG
 
 mutations, the single-strand–specific uracil-DNA 
glycosylase, SMUG1, cannot complement this function. Moreover, the 
 
UNG
 
 mutations lead 
to increased accumulation of genomic uracil. One mutation results in an F251S substitution 
in the UNG catalytic domain. Although this UNG form was fully active and stable when 
expressed in 
 
Escherichia coli
 
, it was mistargeted to mitochondria and degraded in 
mammalian cells. Our results may explain why SMUG1 cannot compensate the UNG2 
deficiency in human B cells, and are fully consistent with the DNA deamination model that 
requires active nuclear UNG2. Based on our findings and recent information in the 
literature, we present an integrated model for the initiating steps in CSR.
 
Recent research revealed a surprising molecular
link between the ancient DNA repair mecha-
nisms and the vertebrate adaptive immune sys-
tem apparently mediated through the nucleo-
base, uracil. Generally, uracil in DNA is the
result of spontaneous or chemical deamination
of cytosine, or misincorporation of dUMP in-
stead of dTMP during replication (for review
see reference 1). Such uracil is removed by
cellular uracil-DNA glycosylases (UDGs),
which initiate a multistep base-excision repair
pathway eventually restoring the correct DNA
sequence. In B cells, uracil in genomic DNA
also may result from enzymatic deamination of
cytosine by activation-induced cytidine deam-
inase (AID). AID is required for somatic hyper-
mutation (SHM) and class switch recombination
(CSR) of Ig genes (2, 3), but its precise role
in antibody diversification has been the focus
of extensive debate (for review see reference
4). Based on its homology with APOBEC-1,
AID initially was suggested to be involved in
RNA editing (5). This view was supported by
apparent dispensability for active uracil-DNA
glycosylase in CSR (6). In the alternative
model, AID specifically catalyses deamination of
cytosine to uracil in single-stranded DNA in Ig
variable and switch regions of activated B cells,
thereby facilitating SHM and CSR, respec-
tively (7, 8). The latter model is supported by a
substantial body of evidence, including results
from Ung-deficient mice (8, 9) as well as human
patients (10). Based on the altered SHM pattern
in the variable region of Ig genes and partially
defective CSR in 
 
Ung
 
 
 
/
 
 
 
 mice, it was suggested
that uracil-DNA glycosylase from the 
 
UNG
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gene is central downstream of AID (8). Furthermore, recent
data indicate that the major route for CSR involves uracil
excision by the uracil-DNA glycosylase, UNG2, with rec-
ognition of U:G mismatches by MutS homologue (MSH)2
providing a backup, at least in mice (9). In contrast, the sec-
ond step in hypermutation, generating mutations at A:T base
pairs, apparently is triggered by mismatch recognition, with
uracil excision providing a backup (9). The involvement of
UNG in CSR and SHM was demonstrated in three unre-
lated hyper-IgM (HIGM) patients (10). The characteristics
of these patients were similar to those associated with AID
deficiency, including susceptibility to bacterial infections and
lymphoid hyperplasia. However, in contrast with the partial
defect CSR observed in the 
 
Ung
 
 
 
/
 
 
 
 mice, these patients
were characterized by a much more severe lack of serum
IgG and IgA; this suggested that the mismatch recognition
system plays a less important role in CSR in humans com-
pared with mice. Surprisingly, other uracil-DNA glycosy-
lases, such as the single-strand–specific monofunctional
uracil-DNA glycosylase (SMUG1), are not able to compen-
sate for UNG deficiency in mice (9), although it was re-
ported to be the major uracil-DNA glycosylase for U:G mis-
matches in mice (11).
Uracil in DNA may be excised by at least four mam-
malian uracil-DNA glycosylases in addition to UNG
(SMUG1, methyl-CpG binding domain 4 glycosylase
[MBD4], thymine-DNA glycosylase [TDG], and Nei-like
glycosylase [NEIL]1). Of these, UNG2 seems to be quan-
titatively dominating in nuclei, with SMUG1 acting as a
backup (12). The substrate preference of SMUG1 in vitro
is similar to that of UNG2, and it remains unknown why
SMUG1 cannot complement the function of UNG2 in
UNG-deficient patients (and mice). To investigate this we
analyzed the major uracil-DNA glycosylase activities in
EBV-immortalized lymphoid cell lines (LCLs) from
UNG-proficient individuals and from UNG-deficient
HIGM patients (P1, P2, and P3; reference 10). Two of
these patients (P1 and P3) carry biallelic germline muta-
tions leading to premature translational stop and catalyti-
cally dead proteins. The third patient (P2) carries a ho-
mozygous missense mutation leading to a phenylalanine to
serine substitution (F251S) in UNG2. The molecular basis
of the HIGM phenotype in patient P2 was studied by ana-
lyzing the enzymatic properties and the intracellular be-
havior of the UNG2-F251 mutant. Finally, we analyzed
the total genomic uracil content in the LCLs to investigate
whether SMUG1 or other uracil-DNA glycosylases could
have different backup functions in the overall genome in
contrast with at Ig loci. Based on the results from the
present study and previous work from our laboratory and
others, we hypothesize that removal of deaminated cy-
tosine from single-stranded Ig switch regions by UNG2 is
essential for CSR that is mediated via a MutS
 
 
 
-indepen-
dent pathway and also important for MutS
 
 
 
-dependent
pathways.
 
RESULTS
UNG2 is the major nuclear uracil-DNA glycosylase in human 
lymphoid cells and SMUG1 contributes insignificantly to 
removal of uracil in single-stranded DNA
 
Here we have focused on the capacity of WT and UNG mu-
tant human LCLs to process uracil in different DNA con-
texts. We first investigated the capacity of nuclear extracts
from an UNG-proficient LCL to remove uracil from single-
stranded compared with double-stranded [
 
3
 
H]dUMP-
labeled calf thymus DNA. To ensure that the putative major
UDGs, UNG2 and SMUG1, were maintained during prepa-
ration of the extracts, immunoprecipitates from nuclear ex-
tracts and total cell lysates were subjected to Western blot
analysis. The results indicated that both proteins were readily
extractable and maintained to a similar extent during prepara-
tion of the nuclear extracts. Furthermore, no bands represent-
ing potential degradation products could be observed; this in-
dicated that UNG2 and SMUG1 remained intact during
extraction (Fig. 1 A). The UDG activity against the ssDNA
substrate was 
 
 
 
2.5-fold higher than with double-stranded
DNA (Fig. 1 B). UNG-neutralizing antibodies inhibited
 
 
 
99% of the activity against both substrates, whereas no ef-
fect was observed with SMUG1-neutralizing antibodies; this
indicated that UNG2 is the major nuclear uracil-DNA glyco-
sylase in the cells, with a preference for ssDNA. When using
[
 
3
 
H]dUMP-labeled calf thymus DNA as substrate, the rela-
tively high substrate concentration used (3.6 
 
 
 
M) would fa-
vor UDGs having high catalytic turnover, such as UNG.
Moreover, U:G-specific UDGs would not be detected using
this substrate. To enhance detection of UDGs with lower
catalytic turnover and high substrate affinity (e.g., SMUG1)
as well as U:G-specific enzymes (e.g., TDG and MBD4), the
extracts were analyzed using a low concentration (0.02 
 
 
 
M)
of a 19-mer [
 
33
 
P]-labeled oligodeoxynucleotide (containing
uracil opposite A or G, or in ssDNA) as substrate and com-
bined with long incubation time (Fig. 1 C). In the presence
of anti-UNG antibodies (lane 2) and Ugi (lane 5), uracil exci-
sion was detectable from the U:A and U:G substrates. This
was attributed mainly to SMUG1, because both activities
were abolished (U:A) or reduced (U:G) in the presence of
anti-UNG and anti-SMUG1 antibodies (lane 4). Although
total uracil excision was most efficient from the single-
stranded DNA (Uss) substrate, almost no activity against the
Uss substrate was detected when UNG was inhibited by anti-
bodies (lane 2) or Ugi (lane 5). SMUG1 originally was de-
scribed (and named) as a single-strand selective monofunc-
tional uracil-DNA glycosylase (13). However, the substrate
preference of SMUG1 is influenced strongly by apurinic/
apyrimidinic endonuclease (APE)1 and the concentration of
salt (12, 14). Therefore, we analyzed and compared UNG2
and SMUG1 activity with purified enzymes using the oligo-
nucleotide substrate described in Fig. 1 C (U:A, U:G, and
Uss) and in the presence of APE1. Under these conditions,
purified human SMUG1 shows a more than 100-fold prefer-
ence for U:G substrate compared with Uss. Furthermore 
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UNG2 is 
 
 
 
1,000-fold more efficient than SMUG1 on Uss
(Fig. 1 D). These substrate activity profiles of UNG2 and
SMUG1 (in the presence of APE1) resemble those seen in
the nuclear extracts, and further support that UNG2 is the
major, if not sole, nuclear glycosylase releasing uracil in Uss
in B cells. This is likely to be important in the UNG-defi-
cient HIGM phenotype, because cytosine deamination by
AID introduces uracil only in ssDNA (15, 16). In conclusion,
UNG2, but not SMUG1, in LCL nuclear extracts excises
uracil from ssDNA very efficiently. Our findings likely ex-
plain the inability of SMUG1 to compensate for UNG2 in B
cells of UNG-deficient HIGM patients and mice.
 
UNG2-F251S is fully active and stable in vitro, but the 
mutation profoundly impairs the expression of active 
protein in B cells
 
The homozygous 
 
UNG
 
 mutations carried by patients P1 and
P3 encode COOH-terminally truncated, and thus, catalyti-
cally dead proteins (10). Thus, the impaired ability to process
AID-generated uracil in Ig loci may explain their HIGM
phenotype. However, this is not obvious for the UNG2-
F251S substitution mutation in patient P2 (Fig. 2 A). Begum
et al. (6) recently reported that the mouse counterpart of this
mutant (denoted F242S) removed uracil and restored CSR
in transfected mouse 
 
Ung
 
 
 
/
 
 
 
 B-cells. To study this apparent
paradox in more detail, we analyzed nuclear extract from the
B cell line derived from patient P2 using the uracil-contain-
ing 19-mer [
 
33
 
P]-labeled DNA-oligo as substrate. No UNG
activity was detected in this assay, thus no inhibitory effect
was achieved with addition of UNG-Ab or Ugi. However,
the extract clearly revealed SMUG1 activity against U:A and
U:G substrates, but not against Uss (Fig. 2 B). To analyze the
effect of the F251S mutation at the protein level, we ex-
pressed UNG2-F251S in 
 
Escherichia coli
 
. Although the ex-
pression level of the mutant protein in the bacteria was con-
siderably lower than that of the WT, the specific activities as
well as the temperature optima and thermal stabilities of the
purified enzymes essentially were identical (Table I, Fig. 2
C). However, this could not rule out the possibility that the
F251S mutation leads to truncated forms of UNG in the B
cells. We previously showed that NH
 
2
 
-terminal truncations
may alter the catalytic properties and protein:protein interac-
tion capabilities of UNG (12, 17, 18). Intact or processed
forms of UNG could not be detected by immunoprecipita-
tion or Western blot analysis in P2 LCL total cell lysates
when using a polyclonal antibody directed against the entire
common catalytic domain of the mitochondrial UNG1 and
nuclear UNG2 proteins (Fig. 2 D). However, more sensitive
and UNG-selective enzymatic assays (using high extract
concentration, increased incubation temperature and time,
and the high turnover substrate) revealed that the P2 LCL
contained trace levels of UNG activity as demonstrated by
the inhibitory effect of neutralizing UNG antibodies (Fig. 2
E). This residual UNG activity amounted to 
 
 
 
0.4% com-
pared with that of the WT control (Fig. 1 B).
Figure 1. UNG2 is the major uracil-DNA glycosylase in B cell 
nuclei. (A) Immunoprecipitation and Western blot analysis of UNG and 
SMUG1 in total and nuclear extracts prepared from the UNG proficient 
control LCL. (B) Total specific UDG activity in UNG-proficient LCL 
nuclear extracts measured by high turnover activity assays using 
36 pmol (1.8  M) [3H]-dUMP labeled calf thymus DNA substrates (gray 
bars: double-stranded substrate; black bars: single-stranded sub-
strate). Extracts (2  g protein) were pretreated with 0.5  g preimmune 
IgGs (0-Ab), neutralizing anti-hUNG (PU101), or neutralizing anti-
hSMUG1 (PSM1) IgGs, or both neutralizing IgGs. (C) UDG activities in 
UNG-proficient LCL nuclear extract measured by low turnover activity 
assays using 0.2 pmol (0.02  M) [33P]-labeled 19-mer deoxyoligonu-
cleotide with uracil in U:A, U:G, or Uss contexts. The samples in lane 
1–4 were pretreated as in (A). Lane 5: nuclear extract was preincubated 
with 10 ng Ugi. Lane 6: samples were treated as in lane 4. In addition, 
200 ng purified UNG2 was included in the reaction. Lane 7: samples 
were treated as in lane 4. In addition, 200 ng purified SMUG1 was 
added to the reaction. Note that two product bands appear to be 
formed consistently. The lower of these bands represents the 9-bp 
product formed by cleavage of the AP site by hot piperidine. The upper 
band represents a 9-bp product in which the AP site has been cleaved 
by AP endonuclease (present in the extracts), before the addition of 
hot piperidine. Such cleavage results in loss of the 3 -phosphate and 
slower migration during PAGE. (D) UDG activity of purified, recombinant 
UNG2 and SMUG1 in the presence of 0.2 pmol purified, recombinant APE1 
was measured using 0.2 pmol [33P]-labeled 19-mer deoxyoligonucleotide 
with uracil in U:A, U:G, or Uss as substrate. Lane 1: 0 pmol UNG2/
SMUG1; lane 2: 0.2 fmol UNG2/SMUG1; lane 3: 2 fmol UNG2/SMUG1; 
lane 4: 20 fmol UNG2/SMUG1; lane 5: 0.2 pmol UNG2/SMUG1; and 
lane 6: 2.0 pmol UNG2/SMUG1. 
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The F251S mutation impairs nuclear accumulation of UNG2 
and causes abnormal translocation to mitochondria via 
interaction with UNG1
 
We previously used human HeLa cells to study intracellular
localization of UNG1- and UNG2-WT and mutants in great
detail (12, 18–21). To study the intracellular behavior of
UNG2-F251S, mutant and WT proteins were expressed as
fluorescent fusion proteins and analyzed in live HeLa cells.
When the cultures were followed for 2 d, an increasingly ab-
errant sorting of the mutant UNG protein was observed, with
a shift toward cytoplasmic accumulation (Fig. 3 A). More-
over, the nuclear fraction of the mutant did not accumulate in
replication foci (Fig. 3 B; reference 18). Coexpression of
UNG2-F251S-EYFP with mitochondrial UNG1-ECFP (Fig.
3 C; reference 21), as well as visualizing the mitochondria
with a monoclonal anti–human mitochondria antibody (Fig.
3 D), demonstrated that the mutant unambiguously colocal-
ized with mitochondria, whereas WT UNG2-EYFP did not.
Moreover, coexpression of the two proteins completely abol-
ished nuclear accumulation of UNG2-F251S-EYFP (Fig. 3
C). The most likely explanation for this is that UNG2-F251S
physically interacts with UNG1, thus redirecting its transloca-
tion from nuclei to mitochondria. Sequestering of UNG2 to
UNG1 likely also promotes proteolytic degradation of the
mutant. Thus, even if significant amounts of enzymatically ac-
tive mutant UNG2-F251S are expressed in vivo in some cells,
its normal nuclear accumulation will be perturbed.
 
Impaired nuclear UNG2 leads to profoundly increased overall 
genomic uracil content
 
To investigate if the inability of SMUG1 or other glycosy-
lases to complement UNG2 in uracil removal was restricted
Figure 2. UNG2-F251S is fully active and stable in vitro, but 
the mutation impairs expression of active protein in B cells. 
(A) Overall structure of the WT UNG complexed with a uracil-containing 
DNA duplex, with F251 highlighted. The close-ups show that F251 is 
surrounded by several hydrophobic side chains, and that the F251S 
substitution results in a “hole” in the central hydrophobic region of 
UNG. (B) P2 nuclear extract analyzed using 0.2 pmol (0.02  M) [33P]-
labeled 19-mer deoxyoligonucleotide with uracil in U:A, U:G, or Uss 
contexts. The samples were pretreated as in Fig 1 B. (C) Temperature 
optimum (left panel) and thermal stability (right panel) of purified, 
recombinant UNG2-WT and UNG2-F251S measured by high turnover 
activity assays using 36 pmol (1.8  M) [3H]-dUMP labeled calf thymus 
DNA substrates. (D, left) Immunoprecipitation and Western blot analysis 
of purified, recombinant UNG2-WT and UNG2-F251S, demonstrating 
that the PU101 antibody precipitates the WT and mutant proteins with 
equal efficiency. (right) IP and Western blot analysis of UNG (using 
PU101) and SMUG1 (using PSM1) in whole cell extracts from P2 
(UNG2-F251S) and C1 (control 1). (E) Trace levels of UNG activity in P2 
nuclear (gray bars) and cytosolic   mitochondrial (black bars) fractions 
measured by high turnover activity assays using 36 pmol [3H]-dUMP 
[3H]-labeled heat-denatured calf thymus DNA substrate under high 
sensitivity assay conditions (4  g protein extracts, 30 min incubation 
at 37 C). Note the higher resolution of the y-axis compared with Fig. 1 B. 
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to Ig loci, we analyzed the overall genomic uracil content in
control and patient LCLs by the comet assay. Although ge-
nomic uracil was not detectable in the controls, the UNG
mutant P1, P2, and P3 cell lines contained substantial levels
of uracil (Fig. 4 A). Thus, SMUG1 cannot perform efficient
sanitation of genomic uracil in any of the LCLs lacking
UNG expression (Fig. 4 A, lower panel). Furthermore, be-
cause clearly visible comets were observed with virtually all
cells in the patient LCLs after UNG treatment (Fig. 4 B),
SMUG1 apparently is unable to compensate for the lack of
overall genomic uracil removal by UNG2 at any stage of the
cell cycle. To investigate whether up-regulation of SMUG1
or other potential backup UDG activities in UNG-deficient
LCLs could be detected at the enzyme activity level, the to-
tal residual UDG activity in the presence of the UNG-spe-
cific inhibitor, Ugi (Fig. 4 C; reference 22), was analyzed in
parallel in LCLs from patients P1–P3 and the controls. In ac-
cordance with the results in Figs. 1 C and 2 B, the removal
of uracil from Uss by SMUG1 was close to the detection
limit in the patient LCLs and in the controls, whereas signif-
icant activity against U:A and U:G could be observed. Fur-
thermore, the enzymatic activity of SMUG1 and other
(U:G-specific) UDGs in the LCLs apparently was not corre-
lated to the UNG status and the overall genomic uracil con-
tent in the cells.
Given the marked preference of SMUG1 for uracil in ds-
DNA, the elevated genomic uracil content in B cells from
UNG-deficient patients may divert SMUG1 away from Uss
in Ig loci. Thus, even if SMUG1, or very few molecules of
active UNG2 (as in P2), theoretically could be sufficient to
fulfill a specific function in CSR and SHM, the competition
by a large overall DNA uracil pool in the patients may con-
tribute to the HIGM phenotype.
 
DISCUSSION
 
Recently, it was demonstrated that overexpression of human
SMUG1 in Ung-deficient mice did not restore CSR (9).
 
Table I.
 
Specific activities and relative substrate preferences 
of purified, recombinant UNG2 and UNG2-F251S measured 
using single-stranded and double-stranded [
 
3
 
H]UMP-labeled 
DNA substrates
 
Substrate
Specific
activity WT
single-stranded/
double-stranded
 
U/mg %
 
UNG2
double-
stranded 1,779 
 
 
 
 71 100 8.5 
 
 
 
 0.2
UNG2-F251S
double-
stranded 1,836 
 
 
 
 209 103 
 
 
 
 11 8.2 
 
 
 
 0.3
UNG2
single-
stranded 15,231 
 
 
 
 325 100 
UNG2-F251S
single-
stranded 15,107 
 
 
 
 496 99 
 
 
 
 3
Figure 3. UNG2-F251S is abnormally translocated to mito-
chondria. (A) WT UNG2-EYFP or UNG2-F251S-EYFP transfected in 
HeLa cells and followed in live cells for 2 d. (B) Control coexpression of 
WT UNG2 with different fluorescent tags (upper row). UNG2-F251S 
and WT UNG2 are localized different in human cells, demonstrated by 
coexpression of UNG2-F251S-EYFP and WT UNG2-ECFP in the same 
cell (lower row). (C) Coexpression of WT UNG1-ECFP and UNG2-EYFP 
demonstrates distinct sorting to mitochondria and nuclei, respectively 
(upper row), whereas coexpression of mutant UNG2-F251S-EYFP and 
UNG1-ECFP abolishes translocation of the mutant to nuclei, while in-
creasing its accumulation at mitochondria. (D) UNG2-F251S-EYFP but 
not WT UNG2-EYFP colocalizes with mitochondria in fixed cells as 
demonstrated using an antibody against human mitochondria. 
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This is in full agreement with our results with human cells;
this indicates that the efficient removal of uracil from DNA
cannot be compensated for by SMUG1 or other DNA gly-
cosylases. The original naming of SMUG1 as a single-strand
selective monofunctional uracil-DNA glycosylase (13) was
based upon the substrate preference of purified, recombinant
 
Xenopus
 
 SMUG1. As demonstrated in our laboratory and by
others, the activity profile of hSMUG1 is different from that
originally reported for xSMUG1, and the activity of the hu-
man enzyme strongly depends on the salt concentrations that
are used in the assays and the presence of APE1 (12, 14).
Thus, at physiologically relevant salt concentrations, the ac-
tivity of recombinant hSMUG1 against Uss is reduced se-
verely; this is confirmed by the present analyses of the LCL
extracts. However, compensatory mechanisms may play dif-
ferent roles in humans and mice because CSR is less affected
in Ung-deficient mice (8) than in 
 
UNG
 
 
 
/
 
 
 
 patients (10).
However, mouse 
 
Msh2
 
 
 
/
 
 
 
Un
 
g
 
 
 
/
 
 
 
 double knockouts proved
to be completely defective in CSR (9) which underscores
the importance of mismatch recognition in CSR in mice.
Contribution by mismatch recognition also may explain re-
cent findings by Begum et al. (6) which indicated that the
precise step at which CSR is blocked differs in murine and
human UNG-deficient B cells.
CSR in UNG mutant human B cells is blocked before
formation of DNA double strand breaks (DSBs; reference
10). In contrast, CSR in murine CH12F3-2 B cells that
overexpressed Ugi was affected at a step downstream of
strand cleavage; this suggested that the catalytic activity of
UNG was dispensable for the DNA-cleavage step in CSR
(6). In addition, several catalytically deficient UNG mutants
were able to rescue CSR in murine 
 
Ung
 
 
 
/
 
 
 
 cells (6). How-
ever, these results should be interpreted in light of the ex-
ceptional catalytic turnover of UNG (k
 
cat
 
 up to 5,000 ura-
cils 
 
 
 
 min
 
 
 
1
 
 from ssDNA; reference 23). Previous work
from our laboratory demonstrated that the UNG mutants
that are able to support CSR (D145N, N204V, H268L)
used by Begum et al. (6) all exhibit residual catalytic activity
between 0.04% and 0.52% (24). This is within the normal
range of activity observed for most other DNA glycosylases
(23), and when overexpressed they still may support CSR
in mouse 
 
Ung
 
 
 
/
 
 
 
 B cells by way of active uracil excision.
However, the double mutants, D145N/N204V and
H268L/D145N, are likely to have a further 100–1,000-fold
reduced activity (24) and probably do not reach the thresh-
old activity that is required to restore CSR, as observed (6).
The finding that the mouse counterpart of hUNG2-F251S
is able to restore CSR in Ung-deficient mouse cells (6) ap-
Figure 4. Steady-state genomic uracil levels are increased in LCLs 
from UNG mutant patients; thus, SMUG1 or other UDGs cannot 
compensate for UNG deficiency. (A) Single cell gel electrophoresis 
(comet assay) of alkali-treated cells. Each of the comets was assigned a 
score for the level of apparent DNA damage (given as arbitrary units, see 
Materials and methods). Cells were treated with recombinant UNG 84
before electrophoresis (black bars) or with buffer alone (open bars). Error 
bars represent the standard deviation calculated from four independent 
experiments (each in duplicate). Immunoprecipitation and Western blot 
analysis of UNG and SMUG1 from the whole cell LCL lysates are shown 
below. (B) Photomicrographs illustrating results from the comet assay. C1 
and UNG mutant P3 cells are representative for all cell lines in the respec-
tive groups. (C) SMUG1 or other UDG activities are not up-regulated in 
UNG-deficient LCLs. Nuclear extracts (2  g protein) from UNG-proficient 
(C1, C2) and UNG-deficient (P1, P2, P3) LCLs were preincubated with 10 ng 
Ugi and subjected to analysis using low turnover activity assays using 
0.2 pmol (0.02  M) [33P]-labeled19-mer deoxyoligonucleotide with uracil 
in U:A, U:G, or Uss contexts. In addition, either 0.5  g preimmune IgGs 
(0-Ab) or neutralizing anti-hSMUG1 IgGs (SMUG1-Ab) were added to 
the extracts. 
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parently stands in contrast with our proposal that the F251S
mutation is the underlying cause of HIGM in P2. However,
mistargeting of UNG2-F251S seems to be linked intimately
to the level of UNG1 expression in the cells. Thus, overex-
pression in HeLa of UNG2-F251S alone leads to partial nu-
clear translocation, whereas concomitant overexpression of
UNG1 or UNG1-F251S leads to nearly complete mito-
chondrial translocation of UNG2. Overexpression of this
mutant from a retroviral vector (6) in the absence of UNG1
likely results in nuclear accumulation of active enzyme, and
thus, restores CSR.
It is not clear whether recognition and excision of uracil
by UNG2 takes place while uracil is in the single-stranded
conformation or to what extent uracil is generated in, and
excised from, DNA:RNA hybrids. However, the present
work demonstrates that deoxyuridine in ssDNA is an excel-
lent substrate for B cell UNG2. This also is likely to be the
case for UNG2 from other human cell types, and conforms
to the results using recombinant UNG2 (Fig. 1 C). Further-
more, we previously showed that UNG from HeLa cells ef-
ficiently removes uracil from poly(dU):poly(rA) (25). Thus,
uracil might well be excised from the template and nontem-
plate strand while still in the ssDNA conformation. Al-
though in the present study we examined the substrate pref-
erence of UNG2 in the presence of EDTA to avoid nuclease
activity in the extracts, the single-strand/double-strand
DNA substrate specificity ratio of UNG2 increases 
 
 
 
40-fold
in the presence of physiological concentrations of Mg
 
2
 
 
 
 (12).
This clearly indicates that Uss is the preferred substrate in
vivo. Removal of uracil from single-stranded Ig loci is sub-
stantiated further by our previous finding that UNG2 con-
tains motifs within its NH
 
2
 
-terminal region that interact
with the single-strand binding, replication protein A (RPA)
(18, 19). Thus, RPA may enhance the recruitment of
UNG2 to Uss in switch regions. Recently, it was demon-
strated that AID also is recruited to transcribed Ig loci by the
single-strand DNA binding protein, RPA (26); this raises the
possibility that the individual steps in CSR are orchestrated
within a multiprotein complex. The availability of UNG2 to
such a complex is probably more important than its high cat-
alytic turnover (which likely is adapted to cope with the
speed of the replication machinery; reference 18). Thus,
UNG2 may have two distinct functions in antibody affinity
maturation: assembly of functional protein complexes and
Figure 5. Integrated model for initiation of CSR. Deamination of 
deoxycytidine in ssDNA close to the transcription complex initiates MutS -
independent (left) and MutS -dependent (middle and right) pathways. 
The MutS -independent pathway requires UNG2 that creates a large 
number of AP sites in both strands. After reannealing, opposing or closely 
spaced AP sites directly generate DSBs by AP-endonuclease (APE1) cleav-
age. When the cellular level (or function) of UNG2 is partially impaired, 
fewer AP sites are generated, and may not sustain DSB formation by direct 
cleavage. However, even a small number of AP sites generated by UNG2 
would be sufficient to create nicks recognized by DNA mismatch repair 
factors and to initiate 5 -3  processing toward MutS  bound to unprocessed 
U:G mismatches. If UNG2 is impaired fully, the MutS -dependent path-
way still may operate—although with strongly reduced efficiency—by 
using alternative nicking factors, such as ERCC1/XPF or TDG/NEIL1/
SMUG1, followed by APE1. In such a scenario, the different pathways are 
likely to function in parallel, and the speed at which individual pathways 
operate may depend on the availability of the various factors at any given 
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excision of uracil. This also would explain the apparent para-
dox that some UNG mutants with low catalytic activity sus-
tain the function in CSR and SHM.
An integrated model for initiation of CSR
CSR has been proposed to occur in mice via an UNG-
dependent pathway (major) and an UNG-independent path-
way (backup); the latter involves mismatch recognition by
MSH2/MSH6 (MutS ; reference 9). This model fails to ex-
plain how the initial strand breaks are formed in a UNG-
independent pathway that ultimately leads to DSBs. In light
of the present findings and recent reports in the literature, we
propose that UNG2 also may be a major player in the path-
way involving MutS . However, the function of UNG2 in
the MutS -pathway likely is redundant, and may be com-
pensated for by other factors (Fig. 5). Both pathways are ini-
tiated by AID that deaminates deoxycytidine in the template
(27) and nontemplate strands (7) of transcribed switch re-
gions. According to the proposed structure model (28) and
in vitro activity analyses (16), AID dimers may accommodate
only a single DNA strand within its active site. Thus, we
speculate that deamination in the template strand takes place
before formation of the RNA:DNA hybrid (e.g., in negative
DNA supercoils upstream of the elongating RNA; reference
29). Recruitment of AID to the growing end of the tran-
scription bubble may be facilitated by interactions with RPA
(26), RNA POLII (30), or both. The nuclear isoform of
UNG2 effectively excises uracil from the nontemplate strand
(this paper), potentially aided by RPA (19). UNG2 also may
act upon the DNA:RNA hybrid downstream of the poly-
merase, because we found previously that UNG effectively
excises uracil from a poly(dU):poly(rA) substrate (25). When
UNG2 is abundant (UNG /  cells), uracils are excised from
both strands and ultimately lead to opposing AP sites at CSR
(e.g., AGCT) hotspots (Fig. 5, left route). AP sites in the
template strand also may destabilize the DNA:RNA hybrid,
and thus, promote reannealing of the DNA strands to gener-
ate substrates for subsequent AP-endonuclease cleavage by
APE1. Opposing AP sites resemble one type of clustered
damage that often is observed after ionizing radiation, and
that leads to a large number of DSBs (for review see refer-
ence 31). Furthermore, it was demonstrated recently that
40–60% of opposing AP sites located at the  1 position of
each other (e.g., as would be expected in AGCT hotspots),
were converted to DSBs within 60 min by mammalian nu-
clear extracts (32).
When the cellular UNG2 level is limited, the density of
AP sites formed by uracil excision may decrease to less than
the threshold sufficient to form DSBs by the direct (MutS -
independent) route. Instead, unprocessed U:G mismatches
may be recognized by the MutS  heterodimer (Fig. 5, mid-
dle and right routes). Processing of such mismatches via the
DNA mismatch repair system has been studied extensively
using nicked substrates, and it was shown recently that hu-
man exonucleus (EXO)1—in conjunction with MutS  and
RPA—supports 5 -3  hydrolysis directed by a 5  strand
break (33). We hypothesize that these substrate 5  strand
breaks may be formed by the sequential action of UNG2
and the AP endonuclease, APE1. Thus, the two pathways
may be collaborating by using common factors to generate
the DSBs that mediate CSR. If UNG2 is totally impaired,
the MutS -dependent pathway may still operate (although
considerably less effectively in humans than in mice) by re-
cruitment of alternative proteins, such as ERCC1/XPF or
NEIL1/SMUG1/TDG. The ERCC1/XPF endonuclease
nicks double-stranded DNA immediately adjacent to 3 –sin-
gle-stranded tails (34) and physically interacts with MSH2
(35); reduced CSR was demonstrated recently in murine
Ercc1 /  B cells (36). Such a model is consistent with the
finding that murine Ung /  B cells have a more pronounced
loss of switch recombination than Msh2 /  cells, and that it
is essentially lost in the double knockouts. Notably, in the
MutS -dependent pathway, very few uracils need to be re-
moved to generate the nicks that are recognized by EXO1-
MutS ; these may be located at a considerable distance from
the recognized mismatch itself, because mismatch-depen-
dent hydrolysis observed in a purified MutS -EXO1 system
extended several thousand nucleotides from the strand break
(33). Notably, a 3 -5  exonucleolytic activity (Fig. 5, right
route) was demonstrated recently for EXO1 in a reconsti-
tuted system made up  of RFC, PCNA, MutS , MutL ,
EXO1, and RPA (33).
How the DSBs are processed downstream of these initi-
ating steps has not been established. Several lines of evidence
suggest that the nonhomologous end-joining apparatus plays
a central role because mouse B cells that are deficient in
ATM (37), H2AX (38), 53BP1 (39), Ku (40), or DNA-PKcs
(41), and patients who have NBS1 or MRE11 deficiency
(42) or ataxia telangiectasia (37) display varying degrees of
perturbed class switching. How these events are orchestrated
at the molecular level, and whether the initiating steps and
downstream processing of the DSBs are organized within
multiprotein complexes remain to be elucidated.
MATERIALS AND METHODS
Cell culture and preparation of total and nuclear cell extracts.
LCLs were prepared as described (10) and maintained in RPMI 1640
Glutamax I (GIBCO BRL) supplemented with 2.5  g/ml fungizone, 100
U/ml penicillin, 100  g/ml streptomycin, and 10% heat-inactivated FBS
(Euroclone) at 37 C and 5% CO2. Nuclear extracts were prepared from
 107 cells (harvested during exponential growth) as described previously
(12), aliquoted, snap frozen in liquid N2, and stored frozen at  80 C until
use. Total cell extracts were prepared from 100 ml culture. Cells were har-
vested and resuspended in 500  l buffer I (10 mM Tris pH 7.8, 200 mM
KCl); thereafter, 500  l buffer II (buffer I containing 2 mM EDTA, 40%
glycerol, 0,5% NP-40, 2 mM DTT, 1  complete protease inhibitors;
Roche) was added. The cell suspension was sonicated for 2 min (duty cycle
25, output 2.5). The extract was aliquoted, snap frozen in liquid N2, and
stored at  80 C until use. Protein concentrations were measured using the
Bio-Rad protein assay using BSA as standard.
UDG activity assays. High-turnover activity assays using [3H]-labeled
nick translated calf thymus DNA substrates (43) were performed essentiallyJEM VOL. 201, June 20, 2005 2019
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as described previously (12). In brief, activity was measured in 20  l assay
mixture containing (final) 20 mM Tris-HCl, pH 7.5, 60 mM NaCl, 1 mM
EDTA, 1 mM DTT, 0.5 mg/ml BSA, 36 pmol [3H]dUMP-labeled calf
thymus DNA substrate and 2  g extract (measured as total protein) at 30 C
for 10 min (or 4  g protein, 37 C for 30 min in high-sensitivity assays).
The amount of released uracil was measured as described previously (25).
Single-stranded [3H]dUMP-labeled calf thymus DNA substrates were pre-
pared by heating double-stranded substrate at 100 C for 10 min followed by
rapid chilling on ice. Purified, recombinant UNG2-WT and the UNG2-
F252S mutant was analyzed in the presence of 7.5 mM MgCl2, as described
previously (12). Low turnover assay was performed using a 19-mer oligode-
oxynucleotide U141 (5 -CATAAAGTGUAAAGCCTGG-3 ; MWG Bio-
tech). U141 was [33P]5 -end labeled, and used as single-stranded substrate
(Uss). Double-stranded substrates were prepared by annealing the labeled
strand to 19-mer complementary strands containing either A or G opposite
uracil (U:A and U:G, respectively). UDG activity was measured in 10  l as-
say mixture containing the same buffer as above. 0.2 pmol [33P]-labeled
oligo-substrate and 2  g nuclear extract (measured as total protein) were in-
cubated at 37 C for 1 h. Purified recombinant UNG2 (0.2 fmol to 2 pmol)
and SMUG1 (0.2 fmol to 2 pmol) were incubated with 0.2 pmol [33P]-
labeled oligo-substrate, 0.2 pmol APE1, and 7.5 mM MgCl2 in the buffer
described above at 37 C for 15 min. Reactions were stopped and abasic sites
cleaved by addition of 50  l 10% piperidine and incubation at 90 C for 20
min. Uracil excision was analyzed as described previously (12).
Immunoprecipitation and Western blot analysis. Immunoprecipita-
tion of UNG and SMUG1 was performed by mixing 2 mg (measured as
protein) of total or nuclear extract with 20  l of paramagnetic protein A
Dynabeads (Dynal) covalently coupled with polyclonal antibodies against
the catalytic domain of UNG (PU101; reference 12) or against SMUG1
(PSM1; reference 12), respectively. Samples were separated on the NuPage
electrophoresis system (Invitrogen) and electro-blotted onto Immobilon
PVDF membranes (Millipore). UNG and SMUG1 were detected using
PU101 or PSM1 primary antibodies, respectively, HRP swine anti–rabbit
(1:5,000; DakoCytomation) secondary antibodies, Super Signal West
Femto substrate (Pierce Chemical Co.), and analyzed on the Kodak Image
Station 2000R.
Heterologous expression and purification of UNG2-WT, UNG2-
F251S, and SMUG1. The F251S mutation was prepared by mutating
pET28a-UNG2 (44) (expressing UNG2 with an NH2-terminal 6xHis-tag)
using the Quick-change site-directed mutagenesis kit (Stratagene) according
to the manufacturer’s protocol. hSMUG1 cloned into pET11a (Invitrogen)
has been published previously (12). The open reading frame of the
hSMUG1 cDNA was excised from pET11a-hSMUG1 as NdeI–BamHI
fragment and subcloned into pET28a (Novagen). pET28a-hSMUG1 en-
codes hSMUG1 with a NH2-terminal 6xHistidine-tag. The APE1 expres-
sion vector (45) was a gift from I. Hickson (Cancer Research UK Laborato-
ries, Oxford, England). The His-tagged proteins were expressed in E. coli
BL21 codon plus-RIL. Cells were lysed by sonication at 4 C in the pres-
ence of 1 mg/ml lysozyme and Complete (Roche) protease inhibitors.
UNG2-WT and UNG2-F251S were purified using Dynabeads Talon ac-
cording to the manufacturer’s protocol. His-tagged SMUG1 and His-
tagged APE1 were purified by Ni-NTA superflow chromatography
(QIAGEN). Both proteins were purified further by MonoS (HR5/5) chro-
matography (Amersham Biosciences).
Mammalian expression constructs and confocal microscopy.
pUNG1-EYFP, pUNG1-ECFP, pUNG2-ECFP, and pUNG2-EYFP were
prepared by replacing the EGFP-tag (AgeI–NotI fragment) in pUNG1-
EGFP and pUNG2-EGFP with the corresponding fragment from pECFP-
N1 and pEYFP-N1 (CLONTECH Laboratories, Inc.; reference 20). In this
vector system, transcription is regulated by the human CMV immediate
early promoter, and thus, allows overexpression of the fusion proteins. The
site-specific mutation, F251S, was made using the Quick-change site-
directed mutagenesis kit. All constructs were verified by DNA sequencing.
Cells were transfected using the calcium phosphate method (Profection,
Promega) according to the manufacturer’s protocol. Fluorescent images of
transfected, freely cycling HeLa cells (1  m thickness) were produced using
a Zeiss LSM Meta laser scanning microscope equipped with a plan-apo-
chromate 63 /1.4 oil immersion objective. ECFP fusions were excited at
    458 nm and detected at     470–500 nm, EYFP fusions were excited
at     514 nm, and detected at     530 nm. Mitochondria were visualized
with a monoclonal mouse anti–human mitochondria primary antibody
(p110, Calbiochem) and a rhodamine (tetra-methyl) conjugated goat anti–
mouse secondary antibody (Molecular Probes) on cells fixed with 2% para-
formaldehyde (5 min) followed by cold methanol ( 20 C) on ice for 10
min. Rhodamine fluorescence was excited at     543, detected at     560,
and visualized using a 63 /1.4 oil immersion objective.
Comet assay. Cultured B cells were pelleted at 400 g or 5 min and em-
bedded in 1% low melting point agarose. After lysis in ice-cold alkaline lysis
solution for 1 h (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris, adjusted to pH
10, 1% Triton X-100). Single-cell gel electrophoresis (comet assay) was per-
formed as described previously (46). Comets were quantified by visual scor-
ing by the same observer in all experiments. 100 comets were selected ran-
domly from each slide and given a value from 0 (undamaged) to 4
(maximum damage); overall scores ranged from 0 to 400 arbitrary units.
Each cell line was analyzed in at least four separate experiments, each time
in duplicate; each sample was evaluated two to five times.
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